Acromegaly in dogs and cats

Ann Endocrinol (Paris). 2021 Apr;82(2):107-111. doi: 10.1016/j.ando.2021.03.002. Epub 2021 Mar 13.

Abstract

Acromegaly is an endocrine disease that leads to elevated production and secretion of growth hormone (GH). It can occur in adult and aged cats and is usually associated with neoplasms, such as functional pituitary macroadenoma of somatotropic cells. In dogs it is usually related to an increase in serum progesterone that induces production of GH by the mammary glands. The main clinical signs are related to insulin resistance and the anabolic effect induced by GH: polyuria, polydipsia, polyphagia, increased tissue growth, weight gain, prognathism, and other changes. The condition can be diagnosed from clinical signals and imaging associated to measurement of serum concentrations of GH and insulin-like growth factor 1 (IGF-1, also known as somatomedin C). The main therapeutic modalities are radiotherapy, hypophysectomy, and several drugs such as somatostatin analogs, dopaminergic agonists and GH receptor antagonists. The present review aims to provide a relevant animal model of acromegaly with an update on the therapeutic approach that may help clinicians to consider the GH axis-IGF-1 system, its pathogenesis and the clinical signs induced by this hormonal disorder.

Keywords: Endocrinopathie; Endocrinopathy; Growth hormone; Hormone de croissance; Hypersomatotropism; Hypersomatotropisme.

Publication types

  • Review

MeSH terms

  • Acromegaly / diagnosis
  • Acromegaly / therapy
  • Acromegaly / veterinary*
  • Animals
  • Cat Diseases* / diagnosis
  • Cat Diseases* / therapy
  • Cats
  • Dog Diseases* / diagnosis
  • Dog Diseases* / therapy
  • Dogs
  • Dopamine Agonists / therapeutic use
  • Growth Hormone / metabolism
  • Hypophysectomy
  • Insulin Resistance
  • Insulin-Like Growth Factor I / physiology
  • Radiotherapy
  • Somatostatin / analogs & derivatives

Substances

  • Dopamine Agonists
  • Somatostatin
  • Insulin-Like Growth Factor I
  • Growth Hormone